Journal of Infectious Diseases & Therapy
Open Access

Abstract

The treatment of drug resistant TB (DR TB) is complicated and lengthy. Sometimes patients fail to appear on each month follow up and the treatment is interrupted. We explored whether the number of months patient has missed follow up during duration of treatment has any impact on the treatment outcomes. We conducted a retrospective data analysis of the patients enrolled on drug resistance tuberculosis (DR TB) from 2009 to February, 2016 at the Indus Hospital, Karachi. The number of enrolled patients till the time of analysis was 895. Still under treatment and transferred out patients were exluded. Hence 623 patients were included in the analysis. The treatment interruption was defined as the discontinuation of treatment for at least for 30 consecutive days. Median age of the patients was 27 years (6 months to 85 years) 298 (46%) were females. 489 (79%) were MDR, 31 (5%) were XDR, 36 (6%) were PDR, 12 (2%) were resistant to Rifampicin only, 55 (9%) were reported to be Rifampicin resistant on GeneXpert. Number of patients who were declared as treatment failure was 51 (8%), 90 (15%) patients died. Overall success rate was 70% and default rate was 7%. Number of patients whose treatment was interrupted for at least 30 consecutive days was 110 (18%). Mean number of days treatment was interrupted was 15 days (0-6 months). Mean number of days treatment was interrupted in the patients who successfully completed the treatment was 16 days and for those with the poor outcomes it was 24 days. After controlling for age, SLD history, gender, presence of co morbid diseases and resistance patterns the multivariate logistic regression showed that the number of months treatment was interrupted was directly associated with poor treatment outcomes (OR 2, 95% CI 1.5-2.2). For this population overall compliance (% of patients who never miss drugs) is 71%.

Biography

Email: rabab.jafri88@gmail.com